FDA claims there’s no estrogen patch shortage as women struggle to get prescriptions filled
Read Original Source
The Food and Drug Administration removed the black box warning from hormone replacement therapies late last year, and recently, the most insured type, the estrogen patch, has been in short supply amid a boom in the therapy’s popularity. Subscribe to read this story ad-free Get unlimited access to ad-free articles and exclusive content. “There’s been a surge in demand for the last two or three years where the utilization of transdermal estrogen has gone up significantly,” said Dr.
AI Summary
Main Idea: The FDA says estrogen patches are not in a national shortage, even as Dr. Marty Makary says demand has risen fast and women report trouble filling prescriptions.
Key Points:
- The FDA says drug makers are still keeping up with demand, though only barely, and it has not added estrogen patches to its shortage list.
- Doctors, pharmacists, and patients say some patch doses are hard to find, and the ASHP shortage list includes 14 patch brands or doses.
- Demand has grown because more women are using hormone therapy, and many are staying on it longer than in the past.
- Experts say women can often switch to another patch brand, another dose, or another form of estrogen, and Sandoz says it has shipped extra supply to the U.S.
Impact on the People
Negative Impact
Women may face delays or higher costs getting estrogen patches, and some may need to switch to other hormone options with different risks or weaker insurance coverage.
Positive Impact
FDA and manufacturers ramping up supply could improve access over time and help more patients keep treatment without major interruption.
How did each entity affect people?
Rate how each entity in this article affected the American people.
- Primary:Dr. Marty Makaryperson
- Major:Sandozcompany
Candidate Entities11 candidates · 5 weighted vote min · 70% decision
- Dr. Marty MakarypersonPrimaryEvaluated
FDA chief quoted making the headline-grabbing claim that there is no estrogen patch shortage.
Include 0 (0%)Ignore 0 (0%)5 to threshold - SandozcompanyMajorEvaluated
Named manufacturer that said it shipped additional supplies to the United States to help meet demand.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Food and Drug Administrationgovernment agency or bodyPrimaryAI selected
Central regulator in the story; its shortage determination and public statements are the main point of dispute.
Include 0 (0%)Ignore 0 (0%)5 to threshold - ViatriscompanyMajorAI selected
Named drugmaker taking steps to expand production of estrogen patches long-term.
Include 0 (0%)Ignore 0 (0%)5 to threshold - American Society of Health-System Pharmacistsnonprofit / NGOContextCandidate
Trade organization whose shortage list includes estrogen patches and is cited as a key counterpoint to the FDA.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Amneal PharmaceuticalscompanyContextCandidate
One of the estrogen patch manufacturers contacted about the shortage.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Dr. Kathleen JordanpersonContextCandidate
Medical officer quoted about patients increasingly having trouble filling prescriptions.
Include 0 (0%)Ignore 0 (0%)5 to threshold
Comments 0
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to comment